Gerold Meinhardt

13.2k total citations · 6 hit papers
58 papers, 4.8k citations indexed

About

Gerold Meinhardt is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gerold Meinhardt has authored 58 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 23 papers in Hepatology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gerold Meinhardt's work include Hepatocellular Carcinoma Treatment and Prognosis (23 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Treatments and Mutations (9 papers). Gerold Meinhardt is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (23 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Treatments and Mutations (9 papers). Gerold Meinhardt collaborates with scholars based in United States, Germany and Spain. Gerold Meinhardt's co-authors include Jordi Bruix, Josep M. Llovet, Won Young Tak, Jiamei Yang, Carol E. Peña, Michael Shan, Chetan Lathia, Yoriko De Sanctis, Keiko Nakajima and Ann‐Lii Cheng and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Gerold Meinhardt

58 papers receiving 4.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

2015 771 citations Jordi Bruix, Tadatoshi Takayama et al. The Lancet Oncology profile →
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial

2016 479 citations Riccardo Lencioni, Josep M. Llovet et al. Journal of Hepatology profile →
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

2012 444 citations Josep M. Llovet, Carol E. Peña et al. Clinical Cancer Research profile →
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

2014 438 citations Andrew X. Zhu, Olivier Rosmorduc et al. profile →
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

2017 421 citations Jordi Bruix, Gerold Meinhardt et al. Journal of Hepatology profile →
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

2023 96 citations Takayuki Yoshino, Maria Di Bartolomeo et al. Nature Communications profile →

Peers

Countries citing papers authored by Gerold Meinhardt

Since Specialization

Citations

This map shows the geographic impact of Gerold Meinhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerold Meinhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerold Meinhardt more than expected).

Fields of papers citing papers by Gerold Meinhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerold Meinhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerold Meinhardt. The network helps show where Gerold Meinhardt may publish in the future.

Co-authorship network of co-authors of Gerold Meinhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Gerold Meinhardt. A scholar is included among the top collaborators of Gerold Meinhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerold Meinhardt. Gerold Meinhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer breakdown → 2023 ·Nature Communications ·Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev A. Wainberg, Élena Elez, J. Rodríguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, (unknown), (unknown)	96
2	Trastuzumab Deruxtecan‒Related Interstitial Lung Disease/Pneumonitis: Computed Tomography Imaging Patterns to Guide Diagnosis and Management 2023 ·JCO Precision Oncology ·Mizuki Nishino, Masahiko Kusumoto, Alexander A. Bankier, Yasuyuki Kurihara, Lin Zhang, Zeshaan A. Rasheed, Gerold Meinhardt, Meena Arunachalam, Corina Taitt, (unknown), Charles A. Powell	6
3	A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies 2020 ·Therapeutic Innovation & Regulatory Science ·(unknown), Alex Dmitrienko, (unknown), Bodo Kirsch, Susanne Lippert, Thomas Schmelter, (unknown), (unknown), H. Schmitz, Matthias Schaefers, Gerold Meinhardt, (unknown), Stephanie Roll	2
4	Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial 2019 ·Clinical Cancer Research ·Marcia S. Brose, (unknown), Michael Jeffers, Christian Kappeler, Gerold Meinhardt, Carol E. Peña	14
5	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial 2019 ·Thyroid ·Olivier Huillard, Anne Jouinot, Camille Tlemsani, Marcia S. Brose, Jennifer Arrondeau, Gerold Meinhardt, Marc Fellous, Yoriko De Sanctis, Martin Schlumberger, François Goldwasser	12
6	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial 2018 ·Journal of Hepatology ·Richard S. Finn, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, René Gerolami, Chiara Caparello, Roniel Cabrera, Charissa Chang, Weijing Sun, (unknown), Annette Baumhauer, Gerold Meinhardt, Jordi Bruix	246
7	Regorafenib as second-line treatment for patients with HCC who progressed on sorafenib: Japanese subgroup analysis of phase 3 RESORCE trial 2017 ·Osamu Yokosuka, Gerold Meinhardt, Jordi Bruix	1
8	Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment 2017 ·Annals of Oncology ·Jordi Bruix, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean–Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, (unknown), Annette Baumhauer, Gerold Meinhardt, Guohong Han	6
9	Exposure–response relationship of regorafenib efficacy in patients with hepatocellular carcinoma 2017 ·European Journal of Pharmaceutical Sciences ·Alexander Solms, (unknown), (unknown), (unknown), Henk‐Jan Drenth, Jordi Bruix, Gerold Meinhardt, Adriaan Cleton, Bart A. Ploeger	18
10	Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial 2016 ·Clinical Cancer Research ·Andrew X. Zhu, Yoon‐Koo Kang, Olivier Rosmorduc, T.R. Jeffry Evans, Armando Santoro, Paul J. Ross, Edward Gane, Arndt Vogel, Michael Jeffers, Gerold Meinhardt, Carol E. Peña	22
11	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial breakdown → 2016 ·Journal of Hepatology ·Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Alfredo Guglielmi, Seung Woon Paik, María Reig, Do Young Kim, Gar-Yang Chau, Angelo Luca, L Ruíz del Arbol, (unknown), (unknown), Kate Nicholson, Gerold Meinhardt, Jordi Bruix	479
12	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial breakdown → 2015 ·The Lancet Oncology ·Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie T.P. Poon, Kwang‐Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabrício Henrique Pereira De Souza, (unknown), Gerold Meinhardt, Josep M. Llovet	771
13	Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours 2007 ·Expert Opinion on Investigational Drugs ·Edwina N. Scott, Gerold Meinhardt, Christian Jacques, Dirk Laurent, Anne Thomas	78
14	Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1 2004 ·Experimental Hematology ·Ralf Schmidmaier, Mark F. Oellerich, Joachim Baumgart, Bertold Emmerich, Gerold Meinhardt	28
15	Antisense CD11b integrin inhibits the development of a differentiated monocyte/macrophage phenotype in human leukemia cells 2002 ·European Journal of Cell Biology ·Igor Prudovsky, К. В. Попов, Sergey Akimov, S. M. Serov, A. V. Zelenin, Gerold Meinhardt, Peter Baier, (unknown), Ralf Hass	19
16	Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways 2000 ·European Journal of Cell Biology ·Gerold Meinhardt, (unknown), (unknown)	32
17	Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival 1999 ·Journal of Molecular Medicine ·Gerold Meinhardt, Clemens-M. Wendtner, Michael Hallek	72
18	Signaling Defect in the Activation of Caspase-3 and PKCδ in Human TUR Leukemia Cells Is Associated with Resistance to Apoptosis 1999 ·Experimental Cell Research ·Gerold Meinhardt, (unknown), (unknown), (unknown), Bertold Emmerich, Ralf Hass	29
19	Specific determination of tyrosine-phosphorylated proteins and peptides by differential iodination 1996 ·Journal of Chromatography A ·(unknown), Gerold Meinhardt, (unknown), Knut Adermann, Peter Schulz‐Knappe, Wolf‐Georg Forssmann, Ralf Hass	2
20	Differential expression of c-myc, max and mxi1 in human myeloid leukemia cells during retrodifferentiation and cell death 1995 ·Leukemia Research ·Gerold Meinhardt, Ralf Hass	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact